|
KMID : 0364820230590030159
|
|
Korean Journal of Microbiology
2023 Volume.59 No. 3 p.159 ~ p.172
|
|
|
Current status of microbiome-based therapeutics research and development
|
|
Jung Hyun-Na
Cho Hyo-Sun
|
|
|
Abstract
|
|
|
|
Recently, several studies have demonstrated that imbalance in the microbiome is associated with several diseases such as cancer, diabetes, allergy, obesity, and infection. Microbiome-based therapeutics are a way to treat these diseases by regulating the human microbiome, which includes prebiotics, probiotics, synbiotics, postbiotics, and fecal microbiota transplantation. These are known to revert an imbalanced microbiome to a healthy state and subsequently contribute to maintaining the homeostasis of the intestinal environment and regulating the immune response. Therefore, microbiome-based therapeutics also improve or synergize the effectiveness of existing therapeutic reagents. However, the differences in efficacy seem to occur depending on various levels of microbiome classes, strains, and administration methods. This review provides a summary of the current research and development status in the field of microbiome-based therapeutics, especially focusing on probiotics, postbiotics, and fecal transplantation.
|
|
|
KEYWORD
|
|
|
fecal microbiota transplantation, microbiome-based therapeutics, postbiotics, probiotics
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|